Test the people most likely to get seriously ill
En el verano austral de 2022, Argentina se enfrentó a una verdad que muchos sistemas sanitarios tardaron en aceptar: la variante Ómicron no podía ser contenida con las mismas herramientas que habían funcionado antes. El gobierno reformuló su estrategia de testeo no como una retirada, sino como una reasignación de recursos hacia quienes más los necesitaban. En ese ajuste —entre la certeza del PCR y la velocidad del autotest— se dibujó una nueva forma de convivir con la incertidumbre pandémica.
- Los centros de testeo colapsaron con la llegada de Ómicron: filas interminables, esperas que se extendían por horas y un sistema de vigilancia epidemiológica al borde del quiebre.
- El gobierno tomó una decisión difícil: abandonar la lógica de 'testar a todos' y priorizar a los sintomáticos sin contacto confirmado, dejando que los contactos estrechos se autoreporten por teléfono sin necesidad de prueba.
- Desde el 6 de enero, cuatro marcas de autotest rápido llegaron a las farmacias, ofreciendo resultados en minutos aunque con una advertencia implícita: la velocidad tiene un costo en precisión.
- Los farmacéuticos se convirtieron en un eslabón inesperado de la vigilancia sanitaria, obligados a cargar cada resultado —positivo, negativo o inválido— en el sistema nacional de salud.
- El sistema no buscaba certeza sino volumen y velocidad: mantener el flujo de datos mientras la infraestructura formal recuperaba el aliento, priorizando a mayores de 60 años, embarazadas e inmunocomprometidos.
Para enero de 2022, la variante Ómicron había desbordado la capacidad de testeo en Argentina. Las filas en los centros sanitarios se extendían por cuadras y el sistema que había rastreado millones de casos desde el inicio de la pandemia comenzaba a ceder. Ante esa presión, el gobierno eligió testear con más inteligencia en lugar de testear más.
Las nuevas pautas establecieron una distinción clara: solo debían hacerse un PCR las personas con síntomas —fiebre, tos, dolor de garganta, pérdida del olfato o el gusto, entre otros— que no fueran contactos estrechos de un caso confirmado. Quienes sí lo eran, y tenían síntomas, simplemente llamaban a un número telefónico y se autorreportaban. La infectóloga Leda Guzzi explicó la lógica: los recursos debían concentrarse en quienes corrían mayor riesgo de enfermarse gravemente.
La otra pieza del nuevo esquema fueron los autotests rápidos, aprobados el 6 de enero para su venta en farmacias. Cuatro marcas —Abbott, Roche, Vyam Group y Wiener— pusieron en manos de la población una herramienta de resultados en minutos, sin necesidad de acudir a un centro médico. Pero el Estado no renunció al registro: los farmacéuticos quedaron obligados a cargar cada resultado en el sistema nacional de vigilancia epidemiológica, y si un cliente no reportaba su resultado, el farmacéutico debía notificar a la autoridad sanitaria local.
El sistema tenía sus límites reconocidos. Los reguladores advirtieron que los autotests ofrecían resultados 'orientativos sin valor diagnóstico concluyente', especialmente en personas con baja carga viral. Un resultado negativo no descartaba la infección. Era una arquitectura diseñada no para la certeza, sino para sostener algún nivel de información mientras la pandemia corría más rápido que las respuestas.
By January 2022, Argentina's testing infrastructure was buckling under the weight of Omicron. The variant had arrived with such velocity that testing centers in cities across the country were overwhelmed—lines stretched around blocks, wait times ballooned, and the system designed to track every infection began to crack. The government had to make a choice: test everyone, or test smarter.
Since the pandemic began, testing had been the backbone of surveillance. Those tests—millions of them—had generated the data that let health authorities understand where the virus was spreading, how fast, and what came next. By January 2022, the world had recorded more than 332 million confirmed cases, nearly all of them identified through testing. But Omicron changed the calculus. The variant was so contagious that the old testing strategy—cast a wide net, catch every case—became impossible to sustain.
Argentina rewrote its testing guidelines. The new rule was simple: if you have symptoms and you are not a close contact of someone with confirmed COVID-19, you need a test. The symptoms were specific—fever of 37.5 degrees Celsius or higher, cough, sore throat, shortness of breath, headache, muscle pain, diarrhea, vomiting, nasal congestion, or sudden loss of taste or smell. There was one exception: people over 60 with risk factors like obesity, diabetes, high blood pressure, or heart or lung disease should get tested if they had symptoms, regardless of contact status. But if you were a close contact of a confirmed case and you had symptoms, you didn't need to go to a testing center at all. Instead, you called a number—148 in Buenos Aires province, a different number in the capital—and reported yourself. The diagnosis would be made by epidemiological connection, not by test.
Dr. Leda Guzzi, an infectious disease specialist at the Argentine Society of Infectology, explained the reasoning to reporters: the health system was under extreme strain. Hospitals and clinics were packed. Testing capacity was finite. The priority had to be the people most likely to get seriously ill—the elderly, pregnant women, those with underlying conditions, and patients already hospitalized with suspected COVID-19. Everyone else would have to manage differently.
This raised a practical problem: how do you test people at home? The answer came from pharmacies. On January 6, Argentina's drug regulatory agency approved four rapid self-tests for sale in pharmacies—made by Abbott, Roche, Vyam Group, and Wiener. These were not the gold-standard PCR tests that could detect even tiny fragments of viral genetic material weeks after infection had cleared. They were faster, simpler, and imperfect. A person could buy one at a pharmacy, take it at home or anywhere else, and get results in minutes. The tests worked regardless of vaccination status or whether the person had symptoms.
But the government built in a reporting mechanism. When someone bought a rapid test at a pharmacy, the pharmacist was responsible for entering the result—positive or negative—into the national health surveillance system. If the person tested positive at home and reported it themselves through their phone, that result would flow back to the pharmacy and then to the national database. Negative results would be logged as "negative, unclassified." Invalid tests would have to be repeated. If a pharmacist never received a report from a customer, the pharmacist had to notify the local health authority.
There was a catch, though. The rapid tests gave what regulators called "orientative results without conclusive diagnostic value"—unless local jurisdictions, in agreement with the national health ministry and based on the epidemiological situation, decided to treat a positive result as a diagnosis. The samples came from the nose or saliva, not the deeper nasopharyngeal swabs used by professionals. If someone had no symptoms or a low viral load—common in the early or late stages of infection—the test might miss the virus entirely. A negative result did not rule out infection. The system was designed not for certainty but for speed and volume, a way to keep some data flowing while the formal testing infrastructure caught its breath.
Citas Notables
People with one or more COVID-19 symptoms who were not close contacts of a confirmed case need to get tested— Dr. Leda Guzzi, infectious disease specialist, Argentine Society of Infectology
The priority for testing must be diagnosis and monitoring of people over 60, pregnant women, people with risk factors, and hospitalized patients with suspected COVID-19— Dr. Leda Guzzi
La Conversación del Hearth Otra perspectiva de la historia
Why did Argentina change the rules so suddenly? Wasn't testing the whole point of tracking the pandemic?
It was, for two years. But Omicron was different—so contagious that testing everyone became physically impossible. The centers were drowning. They had to choose: test everyone and get no one tested, or test the people who mattered most.
And who mattered most?
The elderly, the pregnant, the sick, the immunocompromised. The ones who would end up in the hospital. Everyone else was told to call a phone number if they had symptoms and knew they'd been exposed.
So you could have COVID and never get a test?
Yes. If you were a close contact with symptoms, you reported yourself by phone. No test needed. The diagnosis was made by the chain of exposure, not by a swab.
That seems like it would break the data. How would they know how many cases there really were?
They wouldn't. That was the trade-off. They gave up precision to keep the system from collapsing. And they opened it up—pharmacies could sell rapid tests. People could test themselves at home and report the result. It was messy, but it kept some signal flowing.
Did the rapid tests work?
They worked fast. But they weren't reliable if your viral load was low or if you had no symptoms. A negative result didn't mean you were safe. It just meant the test didn't find the virus that day.